Alzheimer Europe Lunch Debate focusses on improving the diagnosis of dementia

On 10 December, two Innovative Medicines Initiative projects participated in an Alzheimer Europe Lunch Debate. The Lunch Debate was entitled “Improving the diagnosis of dementia – Findings from European research collaborations”.

Sirpa Pietikäinen, who is Member of the European Parliament and Chair of the European Alzheimer’s Alliance, opened the event.

Pierre Krolak-Salmon from the Institut du Vieillissement (Lyon, France) started with the first presentation. He introduced a consensus, developed as part of the Act on Dementia project. The speech focussed on a graduated diagnosis strategy tailored to the patients’ needs and wills. This strategy is based on a consensus that aims at clarifying appropriate components for primary and specialty care. The strategy has been published in a scientific journal and can be accessed here: https://www.ncbi.nlm.nih.gov/pubmed/31594224

Next, Mercè Boada from Fundació ACE (Coordinator of the Models of Patient Engagement for Alzheimer’s Disease project – MOPEAD) presented preliminary results. These included learnings on the effectiveness of the models of patient engagement that were tested and evaluated by the project.

After that, Gill Farrar from GE Healthcare held the closing presentation. Her speech revolved around the AMYPAD project. As part of this, she introduced its endeavours to clarify the role of brain imaging in the diagnosis and prognosis of Alzheimer’s disease.

Collaborators from the MOPEAD project also took the opportunity to share recommendations for policy makers as well as public education material with the attendees.

 

Read more about the event: https://www.alzheimer-europe.org/News/Alzheimer-Europe/Tuesday-10-December-2019-Alzheimer-Europe-holds-lunch-debate-examining-diagnosis-of-dementia

Read more about the recommendations for policy makers and public education materials: https://www.mopead.eu/single-post/2019/12/12/MOPEAD-Policy-Recommendations-and-Public-Awareness-Strategy-now-available